Oncology News

BOSTON — Patients with hepatitis C infection cirrhosis treated with oral direct-acting antiviral agents were not at increased risk for developing hepatocellular carcinoma, according to study findings presented here.

Bayer announced it has submitted a supplemental New Drug Application to the FDA for Stivarga as a second-line systemic treatment for patients with unresectable hepatocellular carcinoma.

The use of transarterial chemoembolization with radiotherapy led to improved survival outcomes for patients with unresectable hepatocellular carcinoma and portal vein tumor thrombus, compared with patients who underwent transarterial chemoembolization alone, per published findings in Hepatology Research.

Researchers developed an effective risk model for measuring long-term outcomes of nodules with undetermined malignant potential and hepatocellular carcinoma progression in patients with hepatitis B virus-related cirrhosis, per published findings in the American Journal of Gastroenterology.

The use of photodynamic therapy with stents was safe and increased survival among patients with unresectable extrahepatic cholangiocarcinoma vs. stents alone, per results from a retrospective study presented at UEG Week 2016.

LAS VEGAS — Black patients presented with more advanced hepatocellular carcinoma compared with non-Hispanic white patients at Alameda Health System, Highland Hospital — a safety-net hospital — in Oakland, Calif., per data presented at ACG 2016.

Cigarette smoking led to a significant number of cancer deaths throughout the United States, according to data published in JAMA Internal Medicine.

Patients who underwent hepatectomy via minimally invasive surgery were less likely to experience serious morbidities or mortality compared with patients who underwent hepatectomy via open surgery, according to data presented at the 2016 Clinical Congress of the American College of Surgeons.

The National Comprehensive Cancer Network Oncology Research Program announced it awarded a grant to study the efficacy of an immunotherapeutic drug and other therapeutic methods as it relates to hepatocellular carcinoma.

A data linkage study from New South Wales, Australia showed hepatitis B-associated hepatocellular carcinoma rates declined in recent years, whereas hepatitis C-associated HCC rates increased.